Transurethral needle ablation for benign prostatic hyperplasia: 12- Month results of a prospective, multicenter U.S. study

Claus Roehrborn, Muta M. Issa, Reginald C. Bruskewitz, Michael J. Naslund, Joseph E. Oesterling, Ramon Perez-Marrero, Bryan P. Shumaker, Perinchery Narayan

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objectives. To report the safety and efficacy of the transurethral needle ablation (TUNA) procedure for the treatment of clinical benign prostatic hyperplasia (BPH). Methods. One hundred thirty patients with BPH were enrolled in two identical protocols and treated by the TUNA procedure. Entry criteria included an American Urological Association symptom index (AUA SI) of 13 points or higher and a peak flow rate of 12 mL/s or less. Patients were followed up for 12 months. Efficacy parameters included the AUA SI, AUA problem index, BPH impact index (BPH II), quality of life (QOL) score, and peak flow rate. At each visit, side effects were elicited. Follow-up data are available for 93 patients at 12 months. All patients were given intraurethral lidocaine augmented by oral and/or parenteral sedation. No patient received spinal or general anesthesia. Results. All patients tolerated the procedure well, and there were no deaths. Forty-one percent of patients (n = 53) had a catheter placed immediately after the procedure. At 12 months, the AUA SI had decreased from 23.7 to 11.9 (P <0.0001) and the BPH II from 7.5 to 2.5 (P <0.0001), whereas the peak flow rate had increased from 8.7 to 14.6 mL/s (P <0.0001). Irritative voiding symptoms were noted in 20 patients (16%) at some point during follow-up. Two patients reported erectile dysfunction, and 1 reported retrograde ejaculation. Conclusions. In this prospective study of 130 patients with clinical BPH and lower urinary tract symptoms, TUNA provided substantive and lasting improvement according to AUA SI, BPH II, and QOL scores as well as peak flow rate over 1 year. The TUNA procedure was well tolerated, with few major side effects and complications noted. Longer follow-up is needed to document the maintenance of clinical benefit beyond 12 months.

Original languageEnglish (US)
Pages (from-to)415-421
Number of pages7
JournalUrology
Volume51
Issue number3
DOIs
StatePublished - Mar 1998

Fingerprint

Prostatic Hyperplasia
Multicenter Studies
Needles
Quality of Life
Lower Urinary Tract Symptoms
Ejaculation
Spinal Anesthesia
Erectile Dysfunction
Lidocaine
General Anesthesia
Catheters
Maintenance
Prospective Studies
Safety

ASJC Scopus subject areas

  • Urology

Cite this

Roehrborn, C., Issa, M. M., Bruskewitz, R. C., Naslund, M. J., Oesterling, J. E., Perez-Marrero, R., ... Narayan, P. (1998). Transurethral needle ablation for benign prostatic hyperplasia: 12- Month results of a prospective, multicenter U.S. study. Urology, 51(3), 415-421. https://doi.org/10.1016/S0090-4295(97)00682-1

Transurethral needle ablation for benign prostatic hyperplasia : 12- Month results of a prospective, multicenter U.S. study. / Roehrborn, Claus; Issa, Muta M.; Bruskewitz, Reginald C.; Naslund, Michael J.; Oesterling, Joseph E.; Perez-Marrero, Ramon; Shumaker, Bryan P.; Narayan, Perinchery.

In: Urology, Vol. 51, No. 3, 03.1998, p. 415-421.

Research output: Contribution to journalArticle

Roehrborn, C, Issa, MM, Bruskewitz, RC, Naslund, MJ, Oesterling, JE, Perez-Marrero, R, Shumaker, BP & Narayan, P 1998, 'Transurethral needle ablation for benign prostatic hyperplasia: 12- Month results of a prospective, multicenter U.S. study', Urology, vol. 51, no. 3, pp. 415-421. https://doi.org/10.1016/S0090-4295(97)00682-1
Roehrborn, Claus ; Issa, Muta M. ; Bruskewitz, Reginald C. ; Naslund, Michael J. ; Oesterling, Joseph E. ; Perez-Marrero, Ramon ; Shumaker, Bryan P. ; Narayan, Perinchery. / Transurethral needle ablation for benign prostatic hyperplasia : 12- Month results of a prospective, multicenter U.S. study. In: Urology. 1998 ; Vol. 51, No. 3. pp. 415-421.
@article{629a3c887f6540889ec72200a1dbc013,
title = "Transurethral needle ablation for benign prostatic hyperplasia: 12- Month results of a prospective, multicenter U.S. study",
abstract = "Objectives. To report the safety and efficacy of the transurethral needle ablation (TUNA) procedure for the treatment of clinical benign prostatic hyperplasia (BPH). Methods. One hundred thirty patients with BPH were enrolled in two identical protocols and treated by the TUNA procedure. Entry criteria included an American Urological Association symptom index (AUA SI) of 13 points or higher and a peak flow rate of 12 mL/s or less. Patients were followed up for 12 months. Efficacy parameters included the AUA SI, AUA problem index, BPH impact index (BPH II), quality of life (QOL) score, and peak flow rate. At each visit, side effects were elicited. Follow-up data are available for 93 patients at 12 months. All patients were given intraurethral lidocaine augmented by oral and/or parenteral sedation. No patient received spinal or general anesthesia. Results. All patients tolerated the procedure well, and there were no deaths. Forty-one percent of patients (n = 53) had a catheter placed immediately after the procedure. At 12 months, the AUA SI had decreased from 23.7 to 11.9 (P <0.0001) and the BPH II from 7.5 to 2.5 (P <0.0001), whereas the peak flow rate had increased from 8.7 to 14.6 mL/s (P <0.0001). Irritative voiding symptoms were noted in 20 patients (16{\%}) at some point during follow-up. Two patients reported erectile dysfunction, and 1 reported retrograde ejaculation. Conclusions. In this prospective study of 130 patients with clinical BPH and lower urinary tract symptoms, TUNA provided substantive and lasting improvement according to AUA SI, BPH II, and QOL scores as well as peak flow rate over 1 year. The TUNA procedure was well tolerated, with few major side effects and complications noted. Longer follow-up is needed to document the maintenance of clinical benefit beyond 12 months.",
author = "Claus Roehrborn and Issa, {Muta M.} and Bruskewitz, {Reginald C.} and Naslund, {Michael J.} and Oesterling, {Joseph E.} and Ramon Perez-Marrero and Shumaker, {Bryan P.} and Perinchery Narayan",
year = "1998",
month = "3",
doi = "10.1016/S0090-4295(97)00682-1",
language = "English (US)",
volume = "51",
pages = "415--421",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Transurethral needle ablation for benign prostatic hyperplasia

T2 - 12- Month results of a prospective, multicenter U.S. study

AU - Roehrborn, Claus

AU - Issa, Muta M.

AU - Bruskewitz, Reginald C.

AU - Naslund, Michael J.

AU - Oesterling, Joseph E.

AU - Perez-Marrero, Ramon

AU - Shumaker, Bryan P.

AU - Narayan, Perinchery

PY - 1998/3

Y1 - 1998/3

N2 - Objectives. To report the safety and efficacy of the transurethral needle ablation (TUNA) procedure for the treatment of clinical benign prostatic hyperplasia (BPH). Methods. One hundred thirty patients with BPH were enrolled in two identical protocols and treated by the TUNA procedure. Entry criteria included an American Urological Association symptom index (AUA SI) of 13 points or higher and a peak flow rate of 12 mL/s or less. Patients were followed up for 12 months. Efficacy parameters included the AUA SI, AUA problem index, BPH impact index (BPH II), quality of life (QOL) score, and peak flow rate. At each visit, side effects were elicited. Follow-up data are available for 93 patients at 12 months. All patients were given intraurethral lidocaine augmented by oral and/or parenteral sedation. No patient received spinal or general anesthesia. Results. All patients tolerated the procedure well, and there were no deaths. Forty-one percent of patients (n = 53) had a catheter placed immediately after the procedure. At 12 months, the AUA SI had decreased from 23.7 to 11.9 (P <0.0001) and the BPH II from 7.5 to 2.5 (P <0.0001), whereas the peak flow rate had increased from 8.7 to 14.6 mL/s (P <0.0001). Irritative voiding symptoms were noted in 20 patients (16%) at some point during follow-up. Two patients reported erectile dysfunction, and 1 reported retrograde ejaculation. Conclusions. In this prospective study of 130 patients with clinical BPH and lower urinary tract symptoms, TUNA provided substantive and lasting improvement according to AUA SI, BPH II, and QOL scores as well as peak flow rate over 1 year. The TUNA procedure was well tolerated, with few major side effects and complications noted. Longer follow-up is needed to document the maintenance of clinical benefit beyond 12 months.

AB - Objectives. To report the safety and efficacy of the transurethral needle ablation (TUNA) procedure for the treatment of clinical benign prostatic hyperplasia (BPH). Methods. One hundred thirty patients with BPH were enrolled in two identical protocols and treated by the TUNA procedure. Entry criteria included an American Urological Association symptom index (AUA SI) of 13 points or higher and a peak flow rate of 12 mL/s or less. Patients were followed up for 12 months. Efficacy parameters included the AUA SI, AUA problem index, BPH impact index (BPH II), quality of life (QOL) score, and peak flow rate. At each visit, side effects were elicited. Follow-up data are available for 93 patients at 12 months. All patients were given intraurethral lidocaine augmented by oral and/or parenteral sedation. No patient received spinal or general anesthesia. Results. All patients tolerated the procedure well, and there were no deaths. Forty-one percent of patients (n = 53) had a catheter placed immediately after the procedure. At 12 months, the AUA SI had decreased from 23.7 to 11.9 (P <0.0001) and the BPH II from 7.5 to 2.5 (P <0.0001), whereas the peak flow rate had increased from 8.7 to 14.6 mL/s (P <0.0001). Irritative voiding symptoms were noted in 20 patients (16%) at some point during follow-up. Two patients reported erectile dysfunction, and 1 reported retrograde ejaculation. Conclusions. In this prospective study of 130 patients with clinical BPH and lower urinary tract symptoms, TUNA provided substantive and lasting improvement according to AUA SI, BPH II, and QOL scores as well as peak flow rate over 1 year. The TUNA procedure was well tolerated, with few major side effects and complications noted. Longer follow-up is needed to document the maintenance of clinical benefit beyond 12 months.

UR - http://www.scopus.com/inward/record.url?scp=0032031254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032031254&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(97)00682-1

DO - 10.1016/S0090-4295(97)00682-1

M3 - Article

C2 - 9510346

AN - SCOPUS:0032031254

VL - 51

SP - 415

EP - 421

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -